Total Payments
$9,480
2024 Payments
$1,888
Companies
39
Transactions
537
Medicare Patients
3,318
Medicare Billing
$5.3M
Payment Breakdown by Category
Food & Beverage$9,262 (97.7%)
Education$218.44 (2.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $9,262 | 533 | 97.7% |
| Education | $218.44 | 4 | 2.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $1,992 | 106 | $0 (2024) |
| ABBVIE INC. | $1,238 | 69 | $0 (2024) |
| PFIZER INC. | $789.46 | 68 | $0 (2024) |
| Janssen Biotech, Inc. | $629.39 | 27 | $0 (2024) |
| UCB, Inc. | $590.99 | 31 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $549.46 | 29 | $0 (2024) |
| Lilly USA, LLC | $430.82 | 28 | $0 (2023) |
| Genentech USA, Inc. | $334.81 | 21 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $276.77 | 12 | $0 (2023) |
| GlaxoSmithKline, LLC. | $232.04 | 16 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,888 | 96 | Amgen Inc. ($385.82) |
| 2023 | $1,913 | 91 | Amgen Inc. ($460.21) |
| 2022 | $1,137 | 63 | Amgen Inc. ($319.26) |
| 2021 | $320.29 | 21 | Amgen Inc. ($152.91) |
| 2020 | $373.61 | 21 | Amgen Inc. ($95.37) |
| 2019 | $1,311 | 81 | AbbVie, Inc. ($300.19) |
| 2018 | $1,390 | 88 | PFIZER INC. ($233.01) |
| 2017 | $1,147 | 76 | Amgen Inc. ($244.06) |
All Payment Transactions
537 individual payment records from CMS Open Payments — Page 1 of 22
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $22.39 | General |
| Category: Inflammation | ||||||
| 12/12/2024 | Alexion Pharmaceuticals, Inc. | STRENSIQ (Biological) | Food and Beverage | In-kind items and services | $22.33 | General |
| Category: Rare Disease | ||||||
| 12/11/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug), UPTRAVI | Food and Beverage | In-kind items and services | $30.86 | General |
| Category: Cardiology | ||||||
| 12/10/2024 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $4.52 | General |
| Category: Inflammation | ||||||
| 12/05/2024 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $22.63 | General |
| Category: Inflammation | ||||||
| 12/05/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $13.15 | General |
| Category: IMMUNOLOGY | ||||||
| 12/04/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $19.27 | General |
| Category: Inflammation | ||||||
| 11/21/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $19.64 | General |
| Category: Dermatology | ||||||
| 11/21/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $18.44 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/14/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $29.11 | General |
| Category: IMMUNOLOGY | ||||||
| 11/07/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $26.73 | General |
| Category: Immunology | ||||||
| 11/05/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $19.43 | General |
| Category: Dermatology | ||||||
| 10/31/2024 | Organon Llc | HADLIMA (Drug) | Food and Beverage | In-kind items and services | $22.60 | General |
| Category: ADALIMUMAB-BWWD | ||||||
| 10/30/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $24.73 | General |
| Category: IMMUNOLOGY | ||||||
| 10/21/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $5.33 | General |
| Category: IMMUNOLOGY | ||||||
| 10/17/2024 | SCILEX PHARMACEUTICALS INC. | GLOPERBA (Drug) | Food and Beverage | In-kind items and services | $24.65 | General |
| Category: Analgesic | ||||||
| 10/16/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $21.24 | General |
| Category: Immunology | ||||||
| 10/15/2024 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $8.38 | General |
| Category: Inflammation | ||||||
| 10/10/2024 | GENZYME CORPORATION | KEVZARA (Biological) | Food and Beverage | In-kind items and services | $22.79 | General |
| Category: Rheumatology | ||||||
| 10/09/2024 | Alexion Pharmaceuticals, Inc. | STRENSIQ (Biological) | Food and Beverage | In-kind items and services | $21.18 | General |
| Category: Rare Disease | ||||||
| 10/03/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $32.28 | General |
| Category: Dermatology | ||||||
| 10/02/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $30.78 | General |
| Category: Immunology | ||||||
| 09/26/2024 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $18.31 | General |
| Category: Inflammation | ||||||
| 09/25/2024 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Food and Beverage | In-kind items and services | $17.21 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 09/19/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $18.80 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 14 | 596 | 113,773 | $2.0M | $939,191 |
| 2022 | 16 | 802 | 123,653 | $2.0M | $1.1M |
| 2021 | 17 | 880 | 116,660 | $2.6M | $1.4M |
| 2020 | 21 | 1,040 | 162,340 | $3.2M | $1.9M |
Total Patients
3,318
Total Services
516,426
Medicare Billing
$5.3M
Procedure Codes
68
All Medicare Procedures & Services
68 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 16 | 10,450 | $615,600 | $351,462 | 57.1% |
| J0717 | Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 24 | 88,800 | $768,400 | $346,422 | 45.1% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2023 | 11 | 10,151 | $304,530 | $106,724 | 35.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 287 | 589 | $113,920 | $49,337 | 43.3% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 25 | 2,580 | $86,700 | $47,524 | 54.8% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 28 | 167 | $44,923 | $16,363 | 36.4% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 16 | 134 | $22,512 | $6,445 | 28.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 50 | 488 | $17,080 | $5,277 | 30.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 36 | 36 | $9,900 | $3,773 | 38.1% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 14 | 99 | $6,831 | $2,111 | 30.9% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2023 | 29 | 41 | $7,831 | $1,983 | 25.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 20 | 23 | $3,185 | $1,284 | 40.3% |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | Office | 2023 | 14 | 62 | $682.00 | $268.60 | 39.4% |
| J3300 | Injection, triamcinolone acetonide, preservative free, 1 mg | Office | 2023 | 26 | 153 | $306.00 | $217.90 | 71.2% |
| J0717 | Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2022 | 25 | 98,400 | $713,400 | $442,410 | 62.0% |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2022 | 14 | 10,225 | $552,150 | $354,485 | 64.2% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2022 | 11 | 8,850 | $265,500 | $103,774 | 39.1% |
| Q5104 | Injection, infliximab-abda, biosimilar, (renflexis), 10 mg | Office | 2022 | 11 | 1,280 | $96,000 | $48,820 | 50.9% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 25 | 2,700 | $66,960 | $46,049 | 68.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 245 | 452 | $85,880 | $37,820 | 44.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 195 | 323 | $43,605 | $20,174 | 46.3% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 34 | 179 | $48,151 | $18,719 | 38.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 66 | 66 | $18,150 | $7,315 | 40.3% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 14 | 135 | $22,680 | $7,004 | 30.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 54 | 537 | $18,795 | $5,979 | 31.8% |
About Dr. Ronald Caldwell, M.D
Dr. Ronald Caldwell, M.D is a Rheumatology healthcare provider based in Hickory, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/16/2006. The National Provider Identifier (NPI) number assigned to this provider is 1982656567.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ronald Caldwell, M.D has received a total of $9,480 in payments from pharmaceutical and medical device companies, with $1,888 received in 2024. These payments were reported across 537 transactions from 39 companies. The most common payment nature is "Food and Beverage" ($9,262).
As a Medicare-enrolled provider, Caldwell has provided services to 3,318 Medicare beneficiaries, totaling 516,426 services with total Medicare billing of $5.3M. Data is available for 4 years (2020–2023), covering 68 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Location Hickory, NC
- Active Since 05/16/2006
- Last Updated 09/06/2011
- Taxonomy Code 207RR0500X
- Entity Type Individual
- NPI Number 1982656567
Products in Payments
- Enbrel (Biological) $1,522
- Cimzia (Drug) $564.26
- XELJANZ (Drug) $505.92
- Humira (Biological) $482.50
- TREMFYA (Drug) $473.05
- RINVOQ (Biological) $429.25
- TALTZ (Drug) $344.06
- ACTHAR (Biological) $334.09
- COSENTYX (Biological) $279.42
- ORENCIA (Biological) $276.77
- COSENTYX (Drug) $270.04
- Rituxan (Biological) $248.64
- SAPHNELO (Biological) $225.31
- KEVZARA (Biological) $194.61
- TAVNEOS (Drug) $184.44
- KRYSTEXXA (Biological) $176.85
- LYRICA (Drug) $171.27
- BENLYSTA (Biological) $154.71
- SKYRIZI (Biological) $151.79
- KRYSTEXXA (Drug) $128.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.